Valence8 US LP Acquires Shares of 8,969 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Valence8 US LP purchased a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 3rd quarter, HoldingsChannel.com reports. The firm purchased 8,969 shares of the specialty pharmaceutical company’s stock, valued at approximately $999,000. Jazz Pharmaceuticals makes up 0.4% of Valence8 US LP’s investment portfolio, making the stock its 13th largest position.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Versant Capital Management Inc raised its holdings in shares of Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 269 shares during the period. Itau Unibanco Holding S.A. bought a new position in Jazz Pharmaceuticals in the second quarter worth approximately $29,000. EverSource Wealth Advisors LLC grew its stake in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. GAMMA Investing LLC grew its stake in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares in the last quarter. Finally, Gladius Capital Management LP bought a new position in Jazz Pharmaceuticals in the second quarter worth approximately $33,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JAZZ has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Robert W. Baird increased their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Finally, Wells Fargo & Company dropped their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $175.33.

Insider Transactions at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,110 shares of company stock valued at $720,160 in the last quarter. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Up 4.9 %

Jazz Pharmaceuticals stock opened at $125.10 on Friday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market capitalization of $7.56 billion, a price-to-earnings ratio of 17.62, a PEG ratio of 0.98 and a beta of 0.57. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17. The business has a fifty day moving average price of $112.92 and a 200-day moving average price of $110.52.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.